Chinese biotechnology powerhouse WuXi AppTec (603259.SS) rebuffed assertions of posing national security risks to the United States, following calls by bipartisan U.S. lawmakers for potential sanctions on the Shanghai-listed firm.
Amid escalating tensions, fueled by concerns over WuXi AppTec’s purported links to the Chinese Communist Party and military, the company asserted its steadfast commitment to transparency and adherence to international standards.
Responding to recent scrutiny from U.S. lawmakers, WuXi AppTec categorically denied any involvement in activities compromising U.S. national security, emphasizing its unwavering dedication to ethical business practices. In a statement released on Sunday, the biotech giant reiterated its stance, reaffirming that it has neither constituted nor harbored intentions detrimental to the United States.
“Our company firmly believes that WuXi AppTec has not, does not, and will not pose a national security threat to the United States,” the statement read, underlining the company’s unequivocal rejection of allegations casting aspersions on its integrity.
Despite mounting pressure and legislative proposals aimed at curbing its operations, WuXi AppTec remained resolute in its position, expressing confidence that any scrutiny by the U.S. government would yield the same conclusion: the absence of national security concerns stemming from its activities.
Moreover, WuXi AppTec sought to clarify misconceptions surrounding its business scope, emphasizing its non-engagement in human genomics endeavors. The company reiterated its commitment to privacy and data protection, assuring stakeholders that its existing operations do not entail the collection or manipulation of human genome data.
As tensions persist and regulatory scrutiny intensifies, WuXi AppTec stands firm in its assertion of innocence, maintaining its focus on advancing global healthcare innovation while navigating the complexities of geopolitical dynamics.